March 30, 2024

Digital Health Applications (DiGAs) on a Fast Track: Insights From a Data-Driven Analysis of Prescribable Digital Therapeutics in Germany From 2020 to Mid-2024 (Preprint)

View Full Paper

Ask AI

Bookmark

Authors

MGMoritz GoeldnerBMW (Germany)SGSara GehderUniversität Hamburg

Discussion

Member takes

Implication

Data-driven analysis demonstrates rapid prescription growth alongside pricing drops for digital therapeutics, highlighting evidence hurdles for permanent listing.

Key Points

Prescriptions for prescribable digital health applications expanded rapidly from 41,000 to 209,000, while top applications captured 82% of all orders.
Prices dropped by roughly 50% following mandatory negotiations, shifting from an initial median of €514 to a settled median of €221 for 3 months.
Analysis of public data sources, directory registries, and clinical study results evaluated 56 digital therapeutics listed in Germany by mid-2024.
Highlights an exclusive reliance on randomized controlled trials for medical benefits, leaving alternative designs and structural endpoints underused.

Cite This Study

Goeldner et al. (2024) studied this question.

synapsesocial.com/papers/68e71ba3b6db643587695560 https://doi.org/10.2196/preprints.59013

View Full Paper

Ask AI

Bookmark

Implication

Data-driven analysis demonstrates rapid prescription growth alongside pricing drops for digital therapeutics, highlighting evidence hurdles for permanent listing.

Digital Health Applications (DiGAs) on a Fast Track: Insights From a Data-Driven Analysis of Prescribable Digital Therapeutics in Germany From 2020 to Mid-2024 (Preprint)

Discussion

Member takes

Implication

Key Points

Cite This Study

Digital Health Applications (DiGAs) on a Fast Track: Insights From a Data-Driven Analysis of Prescribable Digital Therapeutics in Germany From 2020 to Mid-2024 (Preprint)

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider